Glioblastoma is one of the deadliest cancers known to man. While the advent of immunotherapy and other cutting-edge treatments have prolonged life for people afflicted with other types of cancer, the prognosis for glioblastoma has remained relatively constant: just 18 months.
That year-and-a-half can be brutal: bombarding the brain with radiation in an attempt to crush the cancer into submission, often with little success. Glioblastoma is notoriously resistant to therapy, quickly adapting and roaring back with deadly results.
The SPORE is led by Matt Lesniak, MD, chair of Neurological Surgery and the Michael J. Marchese Professor of Neurosurgery, and C. David James, PhD, professor emeritus of Neurological Surgery.
It's not an exaggeration to say that nearly every glioblastoma patient will, unfortunately, succumb to the cancer. It is, in nearly all cases, incurable."
C. David James, PhD, Professor Emeritus of Neurological Surgery
The lethality of glioblastoma and the paucity of effective treatments is what spurred Maciej Lesniak, MD, chair and Michael J. Marchese Professor of Neurosurgery, along with James, to apply for the Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute, to be awarded to the Robert H. Lurie Comprehensive Cancer of Northwestern University. They didn't do this alone: The 2017 arrival of renowned neuro-oncologist Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery and chief of Neuro-Oncology in the Department of Neurology, bolstered the glioblastoma expertise at Northwestern, and his continued leadership has been a tremendous boon to the program, Lesniak said.
Northwestern's Brain Tumor SPORE part of the Lurie Cancer Center is now three years old, and the bench to bedside process is producing results. Under the leadership of Lesniak and James, the SPORE has made advances in understanding the genetic basis of the disease and developed potential therapies that reduce treatment resistance and clinical trials using immunotherapies. The SPORE philosophy of collaboration and team science under one roof is alive and well.
Since The Cancer Genome Atlas (TCGA) published its landmark 2008 analysis of the genetics of glioblastoma, scientists such as Alexander Stegh, PhD, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology, have used that roadmap to guide their research.
"The TCGA gave us this 'periodic table' of genes that are deregulated in glioblastoma," said Stegh, who is also an associate professor of Medicine in the Division of Hematology and Oncology.
Alexander Stegh, PhD, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology, focuses on genetic deregulation that contributes to therapy resistance in glioblastoma.
While some cancers have oncogene activations that are relatively simple to single out, there's an emerging understanding that glioblastoma is caused by variants of many genes. This is why previous attempts at therapies targeting single genes failed, such as those targeting alterations of the EGFR gene, and why Stegh focuses on genetic deregulation that contributes to therapy resistance.
"Rather than going in there with the very ambitious goal of identifying multiple genes and dialing down their expression levels, we take a slightly different approach: How can we specifically downregulate genes that cause therapy resistance, as an adjuvant therapeutic approach," Stegh said.
Stegh has published several papers identifying important genes implicated in glioblastoma therapy resistance, but one gene, called Bcl2L12, was found to be especially amenable to therapeutic delivery.
Combining his genetic expertise with the nanotechnology expertise of Chad Mirkin, PhD, professor of Medicine in the Division of Hematology and Oncology; and the clinical trial expertise of Priya Kumthekar, MD, '08 '11 '12 GME, associate professor of Neurology in the Division of Neuro-oncology, the investigators designed a spherical nucleic acid drug that crossed the blood-brain barrier and primed tumor cells for death.
The trial, published in Science Translational Medicine, was the first of its kind to show that a nano-therapeutic crossed the blood-brain barrier and into brain tumor cells in patients.
"This unique 3D design has the ability to infiltrate tumor cells to correct the genes inside and make them susceptible for therapy-induced killing," Stegh said.
Bcl2L12 was initially identified as a treatment target by Stegh in 2007. "To go from identifying this gene during my postdoctoral work, to get to the point of actually targeting it and establishing proof-of-concept in patients, it's very gratifying," Stegh said. "We are looking forward to building on this success."
A recurrent obstacle in glioblastoma treatment is the blood-brain barrier. Efforts to develop treatments beyond simple chemotherapy are often stymied by the selective permeability of the barrier, but projects in the SPORE are using emerging technologies to break through. Beyond the project using SNA's, a group of investigators led by Lesniak used stem cell "shuttles" to deliver immunotherapy directly to the tumor site.
Neural stem cells have an affinity for the brain, often traveling to areas of injury. Taking advantage of this travel pattern, investigators modified neural stem cells to produce an oncolytic virus, which targets cancer cells and jump-starts the body's immune response.
The phase I clinical trial, published in The Lancet Oncology, found that this approach was safe and tolerable for patients, and even showed signs that the treatment may improve progression-free and overall survival.
"This is the first-in-human clinical trial to test the neural stem cell delivery of an engineered oncolytic adenovirus," Lesniak said.
Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery, and Priya Kumthekar, MD, '11 '12 GME, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology, were co-authors of the study published in Brain. Atique Ahmed, PhD, associate professor of Neurological Surgery, was senior author.
This emphasis on results or clinical trials testing therapies is what unites all members of the Brain Tumor SPORE. Kumthekar, who has a hand in nearly all clinical trials coming out of the SPORE, chalks up their success to two things: planning and people.
"When we are testing drugs in the pre-clinical phase, we are planning the early clinical phase I. When we are in phase I, we are planning phases II and III," Kumthekar said. "We are always planning the next phase with the goal to get drugs that work to patients as fast as possible."
Further, the wealth of bright minds within the Lurie Cancer Center have made collaboration seamless and stimulating for participating faculty. From her work with Stegh and Mirkin, to pre-clinical work with Atique Ahmed, PhD, associate professor of Neurological Surgery, the greatest resource of the Brain Tumor SPORE has been its people, Kumthekar said.
One collaborative project between Kumthekar, Ahmed and Stupp, found that a drug currently used to prevent organ rejection in transplant patients could also reduce chemotherapy resistance in glioblastoma. Published in Brain, investigators found this drug blocks one molecular synthesis pathway used by cancer cells being treated with radiation therapy; when unable to create molecules essential for DNA synthesis, the cancerous cells are more likely to succumb to the therapy and die.
Back-and-forth collaboration between Kumthekar and Ahmed bringing clinical trial and laboratory expertise together is part of why this drug was selected by the Alliance for Clinical Trials in Oncology, part of the National Clinical Trials Network (NCTN). As a lead academic participating site, Lurie Cancer Center provides scientific leadership in the development and conduct of clinical research within the NCTN, and planning for the phase I trial at Northwestern is already in full swing. A potential phase III trial could be at several alliance network locations around the U.S., according to Kumthekar.
"The field is very interested in drug repurposing right now, and this helps us speed availability of drugs to patients," Kumthekar said.
The end goal of patient care is what unites all members of the SPORE from laboratory-based scientists to clinical trial experts and as these therapies march forward through the lengthy process of clinical trial evaluation, some scientists are hopeful that better treatments are just around the corner.
"Over the last ten to fifteen years, our body of knowledge about the molecular characteristics of glioblastoma has increased tremendously," James said. "As we take the information generated by dozens, if not hundreds of labs and analyze individual patient tumors to determine characteristics that can be targeted with specific therapies, I think we will begin to see more rapid progress in effective treatment of this cancer."
Lesniak, James, Stupp, Stegh, Mirkin, Kumthekar and Ahmed are members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and part of the Lou and Jean Malnati Brain Tumor Institute at the Lurie Cancer Center. Lesniak is director of neuro-oncology at the Lurie Cancer Center. Lesniak and James are principal investigators of Lurie Cancer Center's Brain Tumor SPORE.
Go here to read the rest:
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021
- Shifts Away From R-CHOP Treatment Shows Improved EFS and OS Benefit in MCL - Targeted Oncology - September 25th, 2021